Sugi Predict

Sugi Predict / Compounds / SCHEMBL607610

SCHEMBL607610

SCHEMBL607610

CC(=O)NC(CO)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.61
▸ GPR88 Q9GZN0 4/20 0.54
▸ EPHX2 P34913 2/20 0.53
▸ KMT2A Q03164 2/20 0.52
▸ ROCK2 O75116 3/20 0.51
▸ ROCK1 Q13464 3/20 0.51
▸ MAPK13 O15264 1/20 0.51
▸ RPS6KA5 O75582 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ PAK4 O96013 1/20 0.51
▸ PRKCG P05129 1/20 0.51
▸ CDK1 P06493 1/20 0.51
▸ PRKACA P17612 1/20 0.51
▸ RPS6KB1 P23443 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ AKT1 P31749 1/20 0.51
▸ AKT2 P31751 1/20 0.51
▸ CLK2 P49760 1/20 0.51
▸ GSK3A P49840 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8582093 1.00 RIPK1 (0.61) RIPK1GPR88EPHX2KMT2AROCK2
SCHEMBL607611 1.00 RIPK1 (0.61) RIPK1GPR88EPHX2KMT2AROCK2
SCHEMBL14393511 0.85 PRKACA (0.54) RIPK1KMT2AROCK2ROCK1PRKACA
SCHEMBL14393691 0.85 PRKACA (0.54) RIPK1KMT2AROCK2ROCK1PRKACA
SCHEMBL186238 0.85 LMNA (0.61) EPHX2KMT2ALMNASMN1; SMN2
SCHEMBL186416 0.85 LMNA (0.61) EPHX2KMT2ALMNASMN1; SMN2
SCHEMBL186230 0.85 LMNA (0.61) EPHX2KMT2ALMNASMN1; SMN2
SCHEMBL3311541 0.84 RIPK1 (0.60) RIPK1GPR88EPHX2ROCK2ROCK1
SCHEMBL668277 0.84 RIPK1 (0.60) RIPK1GPR88EPHX2ROCK2ROCK1
SCHEMBL4332848 0.84 RIPK1 (0.60) RIPK1GPR88EPHX2ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 — — US claimed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 — — EP claimed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 — — WO claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 — — US claimed
WO-2023072974-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-05-04 — — WO disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 — — WO disclosed
WO-2021224291-A1 TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS MERCK PATENT GMBH (DE) 2021-11-11 — — WO disclosed
US-10349657-B2 Substituted imidazolylcarboxamides as pesticides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2019-07-16 — — US disclosed
US-20190045783-A1 SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2019-02-14 — — US disclosed
US-8658651-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-25 — — US disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 — — US disclosed
EP-1608617-B1 MUSCARINIC AGONISTS LILLY CO ELI (US) 2013-01-09 — — EP disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 — — US disclosed
US-7183307-B2 Pyrazole-derived kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCROPORATED (US) 2007-02-27 — — US disclosed
US-20060178438-A1 Muscarinic agonists ELI LILLY AND COMPANY (IN) 2006-08-10 — — US disclosed
EP-1608617-A1 MUSCARINIC AGONISTS ELI LILLY AND COMPANY (US) 2005-12-28 — — EP disclosed
CN-1178650-C Multiple unit controlled non-independent release pharmaceutical preparations and method for preparing same — 2004-12-08 — — CN disclosed
WO-2004094363-A1 MUSCARINIC AGONISTS ELI LILLY AND COMPANY (US) 2004-11-04 — — WO disclosed
CN-1317959-A Multiple unit controlled non-independent release pharmaceutical preparations and method for preparing same BAYER AG (DE) 2001-10-17 — — CN disclosed
WO-1998027051-A2 CATALYTIC ASYMMETRIC AMIDOHYDROXYLATION OF OLEFINS WITH N-HALO CARBOXAMIDES THE SCRIPPS RESEARCH INSTITUTE (US) 1998-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178438-A1 Muscarinic agonists CHRM3, CHRM1, CHRM5 RIPK1 3655/4885GPR88 64/4885EPHX2 1584/4885
US-20190045783-A1 SUBSTITUTED IMIDAZOLYLCARBOXAMIDES AS PESTICIDES DDT, CYCS, TSNAX RIPK1 2794/4885GPR88 3622/4885EPHX2 1013/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 RIPK1 1329/4885GPR88 642/4885EPHX2 7/4885
US-10349657-B2 Substituted imidazolylcarboxamides as pesticides DDT, CYCS, TSNAX RIPK1 2794/4885GPR88 3622/4885EPHX2 1013/4885
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 RIPK1 2626/4885GPR88 310/4885EPHX2 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.